Follow this innovation
[ via 
] [?]
Preventing Diabetic Cardiovascular Disease
Schepens Eye Research Institute
posted on 03/04/2009
Atherosclerosis-related events such as myocardial infraction and stroke are two- to four- fold more prevalent in adults with diabetes as compared to those without diabetes. The invention focuses on the protein profilin-1 (pfn) as a mediator in diabetic vascular injury. Pfn levels are increased in the aortic endothelium and within atherosclerotic plaques and pfn knockout mice are protected against plaques onset. Circulating levels of profilin-1 could be used to predict the development of cardiovascular events and inhibition of profilin-1 accumulation would prevent the progression of atherosclerotic diseases.Diabetic vascular complications account for the vast majority of mortality occurring in diabetic patients. For at least 20 years, diabetes rates in North America have been increasing substantially affecting more than 20 million people in the United States alone. There is currently no biomarker for the diagnostic of atherosclerosis vascular diseases.
File Number: SERI-147
Other Information:
Investigator(s)
Ph.D Andrius Kazlauskas
Contact
Mary Chatterton, Director of Corporate Alliances. mary.chatterton@schepens.harvard.edu.
This innovation currently is not available for online licensing. Please contact the case manager at Schepens Eye Research Institute for more information.
request more info
ProfileFind more innovations
